
NEWSMAX @NEWSMAX
The frontrunners in a crowded race to develop the first respiratory syncytial virus (RSV) vaccine – Pfizer and GSK - will face scrutiny from a panel of experts at the U.S. Food and Drug Administration this week. https://t.co/KVubJ2kBjP — PolitiTweet.org